Literature DB >> 24384395

Current concepts on integrative safety assessment of active substances of botanical, mineral or chemical origin in homeopathic medicinal products within the European regulatory framework.

Marie-Luise Buchholzer1, Christine Werner2, Werner Knoess3.   

Abstract

For active substances of botanical, mineral or chemical origin processed in homeopathic medicinal products for human use, the adequate safety principles as with other human medicinal products are applied in line with the European regulatory framework. In homeopathy, nonclinical safety assessment is facing a particular challenge because of a multitude and diversity of source materials used and due to rarely available toxicological data. Thus, current concepts applied by the national regulatory authority in Germany (BfArM) on integrative safety assessment of raw materials used in homeopathic medicinal products involve several evaluation approaches like the use of the Lowest Human Recommended Dose (LHRD), toxicological limit values, Threshold of Toxicological Concern (TTC), data from food regulation or the consideration of unavoidable environmental or dietary background exposure. This publication is intended to further develop and clarify the practical use of these assessment routes by exemplary application on selected homeopathic preparations. In conclusion, the different approaches are considered a very useful scientific and simultaneously pragmatic procedure in differentiated risk assessment of homeopathic medicinal products. Overall, this paper aims to increase the visibility of the safety issues in homeopathy and to stimulate scientific discussion of worldwide existing regulatory concepts on homeopathic medicinal products.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Homeopathic medicinal products; Lowest Human Recommended Dose (LHRD); Safety assessment; Threshold of Toxicological Concern (TTC)

Mesh:

Substances:

Year:  2013        PMID: 24384395     DOI: 10.1016/j.yrtph.2013.12.008

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  6 in total

1.  Antibiotic Use in Children with Acute Respiratory or Ear Infections: Prospective Observational Comparison of Anthroposophic and Conventional Treatment under Routine Primary Care Conditions.

Authors:  Harald J Hamre; Anja Glockmann; Reinhard Schwarz; David S Riley; Erik W Baars; Helmut Kiene; Gunver S Kienle
Journal:  Evid Based Complement Alternat Med       Date:  2014-11-18       Impact factor: 2.629

Review 2.  Whole Medical Systems versus the System of Conventional Biomedicine: A Critical, Narrative Review of Similarities, Differences, and Factors That Promote the Integration Process.

Authors:  Erik W Baars; Harald J Hamre
Journal:  Evid Based Complement Alternat Med       Date:  2017-07-13       Impact factor: 2.629

3.  Paradigm-Specific Risk Conceptions, Patient Safety, and the Regulation of Traditional and Complementary Medicine Practitioners: The Case of Homeopathy in Ontario, Canada.

Authors:  Nadine Ijaz
Journal:  Front Sociol       Date:  2020-01-21

4.  Anthroposophic Medicinal Products: A Literature Review of Features, Similarities and Differences to Conventional Medicinal Products, Scientific and Regulatory Assessment.

Authors:  Erik W Baars; Gunver S Kienle; Peter Heusser; Peter A Pedersen; Herman A van Wietmarschen; Helmut Kiene; Tido von Schoen-Angerer; Harald J Hamre
Journal:  Glob Adv Health Med       Date:  2022-03-08

5.  Use and Safety of Anthroposophic Medicinal Products: An Analysis of 44,662 Patients from the EvaMed Pharmacovigilance Network.

Authors:  Harald Johan Hamre; Anja Glockmann; Kirsten Heckenbach; Harald Matthes
Journal:  Drugs Real World Outcomes       Date:  2017-12

6.  Safety of Anthroposophic Medicinal Products: An Analysis of Adverse Drug Reactions from German Pharmacovigilance Databases.

Authors:  Miek C Jong; Herman van Wietmarschen; Anja Glockmann; Erik W Baars; Harald J Hamre
Journal:  Drugs Real World Outcomes       Date:  2021-07-28
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.